Contract Manufacturing Draft Guidance Overly Prescriptive, Out Of Touch – OTC Industry
This article was originally published in The Pink Sheet Daily
Trade groups and firms including GlaxoSmithKline and Merck say FDA’s draft guidance on quality agreements between drug contract manufacturers and marketers goes into excessive detail and is inconsistent with actual business arrangements common in the industry.
You may also be interested in...
“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
FDA and FTC's latest warning letters include the first firm marketing CBD products linked with bogus COVID-19 claims. Latest warnings also mark the first the agencies submitted based completely or nearly entirely on regulatory violations found in businesses social media postings.